Molecular mechanisms and systemic targeting of NRF2 dysregulation in cancer.


Journal

Biochemical pharmacology
ISSN: 1873-2968
Titre abrégé: Biochem Pharmacol
Pays: England
ID NLM: 0101032

Informations de publication

Date de publication:
07 2020
Historique:
received: 02 02 2020
accepted: 24 04 2020
pubmed: 4 5 2020
medline: 15 12 2020
entrez: 4 5 2020
Statut: ppublish

Résumé

NF-E2-related factor 2 (NRF2) is a master regulator of redox homeostasis and provides cellular protection against oxidants and electrophiles by inducing the expression of a wide array of phase II cytoprotective genes. Until now, a number of NRF2 activators have been developed for treatment of chronic diseases and some are under evaluation in the clinical studies. On the other hand, accumulating evidence indicates that NRF2 confers chemoresistance and radioresistance, and its expression is correlated with poor prognosis in cancer patients. Studies in the last decade demonstrate that diverse mechanisms such as somatic mutations, accumulation of KEAP1 binding proteins, transcriptional dysregulation, oncogene activation, and accumulation of reactive metabolites contribute to NRF2 activation in cancer. In the present review, we illustrate the molecular mechanisms governing the function of NRF2 and explain how they are hijacked in cancer. We also provide some examples of NRF2 inhibitors together with a brief explanation of their mechanisms of action.

Identifiants

pubmed: 32360363
pii: S0006-2952(20)30230-6
doi: 10.1016/j.bcp.2020.114002
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
KEAP1 protein, human 0
Kelch-Like ECH-Associated Protein 1 0
NF-E2-Related Factor 2 0
NFE2L2 protein, human 0
Quassins 0
brusatol 14907-98-3
Tretinoin 5688UTC01R

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

114002

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Jong-Su Kang (JS)

College of Pharmacy and Integrated Research Institute for Drug Development, Dongguk University, 32 Dongguk-ro, Goyang, Gyeonggi-do 10326, Republic of Korea.

Le Ba Nam (LB)

College of Pharmacy and Integrated Research Institute for Drug Development, Dongguk University, 32 Dongguk-ro, Goyang, Gyeonggi-do 10326, Republic of Korea.

Ok-Kyung Yoo (OK)

College of Pharmacy and Integrated Research Institute for Drug Development, Dongguk University, 32 Dongguk-ro, Goyang, Gyeonggi-do 10326, Republic of Korea.

Young-Sam Keum (YS)

College of Pharmacy and Integrated Research Institute for Drug Development, Dongguk University, 32 Dongguk-ro, Goyang, Gyeonggi-do 10326, Republic of Korea. Electronic address: keum03@dongguk.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH